3 assets in Nested Variant Infiltrating Bladder Urothelial Carcinoma

Therapeutic assets addressing Nested Variant Infiltrating Bladder Urothelial Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Nested Variant Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Nested Variant Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Nested Variant Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)